Contract Manufacturing, General

Sterling Pharma Signs Agreement to Support COVID-19 Treatment Development

July 29, 2020

Sterling Pharma Solutions has signed a deal with Moleculin Biotech to support the development of WP1122, a potential COVID-19 treatment.

Contractors Balance Increased Demand During COVID-19

July 01, 2020

BioPharm International

The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.

Fujifilm Diosynth Biotechnologies Reserves Capacity for COVID-19 Therapeutics Accelerator

May 04, 2020

Fujifilm allocates production volumes for COVID-19 treatments in 2021 at its Denmark facility.

Biomanufacturing: Demand for Continuous Bioprocessing Increasing

May 01, 2020

BioPharm International

But are innovations sufficient to increase adoption? CMOs are demanding better continuous bioprocessing options.

Catalent to Manufacture J&J’s Lead COVID-19 Vaccine Candidate

April 30, 2020

Catalent and Johnson & Johnson announce joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity.

Biologics and Compounding Rules Change

March 05, 2020

FDA issued a notice to drug compounders regarding the transition of licensure of biologics to the Public Health Service Act.

Biopharma Contract Market Update

February 15, 2020

BioPharm International

CMOs and CDMOs expanded their services and facilities in 2019 and early 2020.

Building Strategic Relationships with CROs

February 15, 2020

BioPharm International

How to adopt win-win strategies and understand quality agreements for complying with cGMP when building strategic relationships with pharmaceutical contract research organizations.

Growth in Biologics Market Inspires Outsourcing

February 01, 2020

BioPharm International

CDMOs and CMOs will continue to invest in biopharmaceutical services and facilities as the bio/pharmaceutical industry looks to biosimilars and personalized medicine.

Catalent to Supply BeiGene’s Brukinsa

November 25, 2019

The companies announced a commercial supply agreement following FDA’s accelerated approval.